Peregrine Pharmaceuticals Announces Patent Grant for Vasopermeation Enhancement Technology

Review of Peregrine's Anti-VEGF Technology Presented at Third Annual Angiogenesis Conference

Review of Peregrine's Anti-Phospholipid Therapy Program Presented at Second International Conference on Vascular Targeting

Peregrine's Vascular Targeting Agent Technology Presented at Second International Conference on Vascular Targeting

Peregrine Pharmaceuticals Provides Company Update

Peregrine Pharmaceuticals Finalizes Agreement to Evaluate VTA Platform for Treatment of Ocular Disease

Peregrine Pharmaceuticals Announces Publication of Data Related to Its Tumor Necrosis Therapy Technology Platform

Peregrine's VTA Inhibits Growth of Breast Cancer Tumor Metastases by up to 58 Percent

Peregrine's Anti-Angiogenesis Agent Inhibits Growth of Blood Vessels by up to 85% in Breast Cancer Tumor Metastases

Peregrine's VTA & Docetaxel Combination Therapy Inhibits Human Breast Cancer Growth by 93% in Pre-Clinical Studies